Rethink praises Ontario's decision to provide breast cancer patients with Herceptin
Today, Rethink Breast Cancer (Rethink) applauds the Ontario government's decision to provide breast cancer patients with tumours less than or equal to 1 cm access to the revolutionary drug Herceptin under the new Evidence Building Program.
Linear Mode
